999 East Arques Avenue
United States - Map
Pharmacyclics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of small-molecule drugs for the treatment of cancer and immune mediated diseases. Its principal products candidates in clinical development include ibrutinib, which is under multiple Phase III studies in hematologic malignancies; a BTK inhibitor lead optimization program targeting anti-inflammatory and autoimmune indications; PCI-27483, an inhibitor of Factor VIIa that is in phase II clinical trial for the treatment of pancreatic cancer; and a HDAC inhibitor abexinostat, which is in Phase I and II clinical trials for the treatment of solid tumors and hematological malignancies. The companys clinical development and product candidates are small-molecule enzyme inhibitors designed to target key biochemical pathways involved in human diseases with critical unmet needs. It has a collaboration and license agreement with Janssen Biotech, Inc. to develop and commercialize ibrutinib and other structurally related compounds; collaboration and license agreement with Les Laboratoires Servier to develop and commercialize abexinostat; and license agreement with Novo Nordisk A/S to research and develop PCI-27483. Pharmacyclics, Inc. was founded in 1991 and is headquartered in Sunnyvale, California.
|Pharmacyclics Inc.’s ISS Governance QuickScore as of Jun 1, 2013 is 5. The pillar scores are Audit: 1; Board: 8; Shareholder Rights: 4; Compensation: 5.|
|Brought to you by Institutional Shareholder Services (ISS)|
|Mr. Robert W. Duggan ,
Chairman and Chief Exec. Officer
|Mr. Joshua T. Brumm ,
Principal Financial Officer, Principal Accounting Officer and Exec. VP of Fin.
|Dr. Mahkam Zanganeh D.D.S.,
Chief Operating Officer
|Mr. Rainer M. Erdtmann ,
Sr. VP of Investor Relations and Admin.
|Dr. Lori Anne Kunkel M.D.,
Chief Medical Officer
|Amounts are as of Dec 30, 2012 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.|
|Currency in USD.|